Ibere Pharmaceuticals
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBER research report →
Price Chart
About the company
Ibere Pharmaceuticals currently lacks significant operational activities, with its core mission focused on executing a business combination. This could involve a merger, an acquisition of assets or shares, or a corporate restructuring with one or more other entities. The company was founded in 2020 and is based in Philadelphia, Pennsylvania.
- CEO
- Osagie O. Imasogie
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on IBER
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $175.60M
- P/E
- 29.94
- PEG
- 0.02
- P/S
- 0.00
- P/B
- 0.92
- EV/EBITDA
- -174.45
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 2.46%
- ROIC
- -0.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,004,000+0.0%
- Op Income
- $-1,004,000
- Net Income
- $1.56M+0.0%
- EPS
- $0.34+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $10.75
- 52W Low
- $9.75
- 50D MA
- $10.14
- 200D MA
- $9.95
- Beta
- 0.00
- RSI (14)
- 59
- Avg Volume
- 84.33K
No earnings-call transcripts are available for IBER yet.
- Free Float
- 72.3%
- Shares Outstanding
- 17.25M
- Float Shares
- 12.47M
of shares held by institutions
48 13F filers
Buy/sell ratio 0.20. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Spring Creek Capital LLC | 400.00K | 0 |
| Omni Partners Us LLC | 58.55K | ▼ 15.59K |
| Knott David M | 36.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 2, 21 | Vollmer Louis J. | buy | 10,000 |
| Feb 25, 21 | Kerekes Zoltan | other | 3,350,000 |
| Feb 25, 21 | PIPV Capital LLC | other | 3,350,000 |
| Feb 25, 21 | IMASOGIE OSAGIE O | other | 3,350,000 |
| Feb 25, 21 | Vollmer Louis J. | other | 25,000 |
| Feb 25, 21 | Gray Lisa M. | other | 3,350,000 |
| Feb 25, 21 | UKWU HENRIETTA | other | 25,000 |
| Feb 25, 21 | Jones Elaine V | other | 25,000 |
| Feb 25, 21 | Johnson Calvin B. | other | 25,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IBER coverage
Recent articles, reports, and earnings notes.
No research on IBER yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IBER report →IberAmerican Responds to Recent Promotional Activity Pursuant to OTC Markets' Request
newsfilecorp.com · May 31
Cboe Canada Continues to Fuel the Innovation Economy With Public Launch of IberAmerican Lithium
businesswire.com · Sep 13
Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report
prnewswire.com · May 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.